[Secondary effects of prolonged levodopa therapy in Parkinson's disease].
D000367:Age Factors; D000368:Aged; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000009:adverse effects; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001971:Bromocriptine / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D004421:Dystonia / Q000139:chemically induced; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*
D000929:Antidepressive Agents, Tricyclic; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001971:Bromocriptine; D007980:Levodopa; D000547:Amantadine
Efectos secundarios de la levodopaterapia prolongada en la enfermedad de Parkinson.